Here are the latest stories being discussed in biopharma today:

Despite significantly boosting its sales guidance by $2B, pharmaceutical giant Eli Lilly continues to work through supply constraints for its in-demand weight loss and diabetes products. Executives warn that demand for these products, despite manufacturing expansion, may still exceed supply throughout the year.

Meanwhile, the Federal Trade Commission (FTC) is tackling what it refers to as ‘junk’ patents; deploying a new wave of warnings to companies regarding their products for obesity, diabetes, asthma, COPD and severe hypoglycemia.

UnitedHealth Group’s CEO, Andrew Witty, is set to testify before lawmakers over the company’s response to cyberattacks on its technology platform, Change Healthcare.

In other news, Real Chemistry has launched a one-stop dashboard platform dubbed IRIS. This will provide real-time data including clinical trial tracking, script and claims information, consumer behaviors, payer policies, market access news, and communications and media.

As part of its plans for an advisory committee overhaul, the FDA is seeking public input on the best way to construct committees and make their purpose known to the public. A public meeting is pencilled in for June 13th.

Finally, Eli Lilly has discontinued several trials from its pipeline including those involving the cancer drug Verzenio and its partnered drug Jardiance with Boehringer Ingelheim. It also cancelled a Phase 2 trial for a gene therapy acquired through its purchase of Prevail Therapeutics.